Tramadol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tramadol: From Opioid Analgesic to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Tramadol is a centrally-acting opioid analgesic (μ-opioid receptor agonist plus norepinephrine/serotonin reuptake inhibitor) used broadly for moderate to moderately severe pain; no Taiwan license or original-indication text is on record in this evidence pack. The TxGNN model’s top-ranked prediction is Acromesomelic Dysplasia, Hunter-Thompson Type, a rare GDF5-related skeletal disorder, but this ranking is supported by 0 clinical trials and 0 publications, and the evidence pack itself flags the mechanistic link as biologically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no TFDA license record; tramadol is generally used as an opioid analgesic for moderate–severe pain) |
| Predicted New Indication | Acromesomelic Dysplasia, Hunter-Thompson Type |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Taiwan Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for tramadol was not available in this evidence pack (flagged as a High-severity data gap). Based on generally established pharmacology, tramadol is a weak μ-opioid receptor agonist combined with inhibition of norepinephrine and serotonin reuptake, and is used clinically for pain management.
Acromesomelic Dysplasia, Hunter-Thompson Type, however, is a rare monogenic skeletal dysplasia caused by GDF5 mutations, with a pathology rooted in cartilage/bone development rather than pain signaling or inflammation. The evidence pack’s own rationale states there is no disease-modifying mechanistic relationship between tramadol’s analgesic pathway and this disorder, and attributes the high TxGNN score to embedding-space clustering of skeletal/joint-related diseases rather than genuine pharmacological plausibility.
Of the ten predictions reviewed, only rank 7 (juvenile idiopathic arthritis) has any supporting literature, and even that is indirect (name co-occurrence rather than tramadol-specific studies). The remaining nine, including the top-ranked prediction, are unsupported by any clinical trial or publication evidence and are explicitly characterized as likely KG noise.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No approved license records are available — tramadol is currently not marketed in Taiwan per this evidence pack (0 licenses on file).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Acromesomelic Dysplasia, Hunter-Thompson Type, score 99.99%) has zero clinical trial or literature support and is explicitly assessed in the evidence rationale as lacking pharmacological plausibility — the evidence level is L5 (model prediction only), which does not meet the bar for further clinical evaluation.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001, Blocking) — required before any S1 safety screening
- Tramadol mechanism-of-action data from DrugBank (DG002, High)
- If pursuing a repurposing candidate from this drug, consider redirecting attention to rank 7 (juvenile idiopathic arthritis), which has indirect literature support and a “Research Question” designation, and would require tramadol-specific pediatric pain studies to substantiate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.